Lung function improvements with twice-daily aclidinium/formoterol fixed-dose combination in two 24-week studies in patients with COPD

Background: Combining bronchodilators with complementary mechanisms of action may improve lung function in patients with COPD. A fixed-dose combination (FDC) of the long-acting muscarinic antagonist aclidinium bromide and the long-acting β2 agonist formoterol fumarate is in clinical development. Aim: To assess bronchodilation with aclidinium/formoterol FDC in patients with moderate-to-severe COPD. Methods: In two multicentre, randomized Phase III studies (ACLIFORM and AUGMENT) patients were randomized to 24 weeks' double-blind treatment with inhaled aclidinium/formoterol FDC 400 µg/12 µg or 400 µg/6 µg, aclidini…